fluoxetine and Idiopathic Parkinson Disease studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Research Excerpts

Excerpt	Relevance	Reference
"The cardinal motor symptoms of Parkinson's disease (PD) include resting tremor, akinesia, bradykinesia, and rigidity, and these motor abnormalities can be modeled in rodents by administration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibitor tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b hexahydrobenzo[a]quinolizin-2-one; TBZ)."	7.81	Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism. ( Contreras-Mora, HM; Correa, M; Milligan, MN; Podurgiel, SJ; Purcell, LJ; Salamone, JD; Yohn, SE, 2015)
"There are no effective treatments for multiple system atrophy (MSA)."	7.01	Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. ( Azulay, JP; Cochen de Cock, V; Corvol, JC; Couratier, P; Damier, P; Defebvre, L; Durif, F; Fabbri, M; Foubert-Samier, A; Geny, C; Houeto, JL; Meissner, WG; Pavy-Le Traon, A; Perez-Lloret, S; Rascol, O; Remy, P; Rousseau, V; Sommet, A; Thalamas, C; Tison, F; Tranchant, C; Verin, M, 2021)
"The occurrence of a pathological gambling behavior in a 61-year-old patient with idiopathic Parkinson's disease treated with dopaminergic drugs is reported."	6.42	[Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine]. ( Bagheri, H; Montastruc, JL; Schmitt, L, 2003)
"To examine the effects of fluoxetine and repetitive transcranial magnetic stimulation (rTMS) on regional cerebral blood flow (rCBF) using SPECT in patients with PD and depression."	5.12	Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. ( Barbosa, ER; Bermpohl, F; Buchpiguel, C; Fregni, F; Marcolin, MA; Ono, CR; Pascual-Leone, A; Santos, CM; Valente, KD, 2006)
"We report here the case of a patient with fluoxetine and selegiline induced serotonin syndrome, which presented as encephalopathy, generalized myoclonias, fever, stiffness and sweating, complicated with acute renal failure, rhabdomyolysis and disseminated intravascular coagulation findings."	4.81	[Serotonin syndrome: report of a fatal case and review of the literature]. ( Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N, 2002)
"The cardinal motor symptoms of Parkinson's disease (PD) include resting tremor, akinesia, bradykinesia, and rigidity, and these motor abnormalities can be modeled in rodents by administration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibitor tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b hexahydrobenzo[a]quinolizin-2-one; TBZ)."	3.81	Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism. ( Contreras-Mora, HM; Correa, M; Milligan, MN; Podurgiel, SJ; Purcell, LJ; Salamone, JD; Yohn, SE, 2015)
"The accumulation of alpha-synuclein in Lewy bodies and Lewy neurites of different neuronal populations is one of the neuropathological hallmarks in Parkinson disease (PD)."	3.78	Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. ( Barlow, C; Carter, T; Kohl, Z; Mante, M; Masliah, E; Münch, M; Rockenstein, E; Ubhi, K; Winkler, J; Winner, B, 2012)
"A selective, sensitive, simple, and rapid method for the simultaneous determination of fluoxetine (FL) and norfluoxetine (nor-FL) was developed and validated, and further applied to analyze plasma samples obtained from FL-treated patients with Parkinson disease (n = 18)."	3.73	Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study. ( Djordjevic, S; Kovacevic, I; Miljkovic, B; Pokrajac, M; Vuksanovic, J, 2005)
"There are no effective treatments for multiple system atrophy (MSA)."	3.01	Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. ( Azulay, JP; Cochen de Cock, V; Corvol, JC; Couratier, P; Damier, P; Defebvre, L; Durif, F; Fabbri, M; Foubert-Samier, A; Geny, C; Houeto, JL; Meissner, WG; Pavy-Le Traon, A; Perez-Lloret, S; Rascol, O; Remy, P; Rousseau, V; Sommet, A; Thalamas, C; Tison, F; Tranchant, C; Verin, M, 2021)
"The unified Parkinson's disease rating scale (UPDRS), activities of daily living (ADL), Hamilton rating scale for depression (HRSD), Beck depression inventory (BDI), and mini-mental state examination (MMSE) were assessed by a rater blinded to treatment arm."	2.71	Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. ( Barbosa, ER; Fregni, F; Gallucci-Neto, J; Marcolin, MA; Myczkowski, ML; Pascual-Leone, A; Rigolino, R; Santos, CM; Valente, KD, 2004)
"All records were reviewed from a Parkinson's disease clinic to determine how many patients were treated simultaneously with selegiline and fluoxetine."	2.67	Fluoxetine and selegiline--lack of significant interaction. ( Waters, CH, 1994)
"The occurrence of a pathological gambling behavior in a 61-year-old patient with idiopathic Parkinson's disease treated with dopaminergic drugs is reported."	2.42	[Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine]. ( Bagheri, H; Montastruc, JL; Schmitt, L, 2003)
" In this study we investigated the effect of chronic administration of buspirone and fluoxetine on cerebrospinal fluid (CSF) levels of inflammatory cytokines, TNF-α, IL-1β and IL-6 in 6-hydroxydopamine (6-OHDA)-lesioned rats."	1.42	Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats. ( Farajnia, S; Haddadi, R; Nayebi, AM; Sharifi, H, 2015)
" The present study indicates that already a moderate lesion of dopaminergic neurons induces "depressive-like" behaviour in animals which is reversed by chronic administration of the antiparkinsonian drug, pramipexole."	1.40	Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease. ( Berghauzen-Maciejewska, K; Dziubina, A; Głowacka, U; Kolasiewicz, W; Kuter, K; Ossowska, K; Wardas, J, 2014)
" However, long-term administration of L-DOPA can induce abnormal side effects."	1.38	Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model. ( Abe, M; Inden, M; Kitamura, Y; Minamino, H; Takata, K; Tooyama, I; Yoshimoto, K, 2012)
"Treatment with fluoxetine (10 mg/kg, i."	1.31	Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. ( Kannari, K; Matsunaga, M; Shen, H; Suda, T; Yamato, H, 2001)
"Depression is commonly associated with idiopathic Parkinson's disease."	1.29	Anticholinergic effects in a depressed parkinsonian patient. ( Huszonek, JJ, 1995)

Research

Studies (36)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

The Number All Types of Adverse Events.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	13 (36.11)	18.2507
2000's	13 (36.11)	29.6817
2010's	9 (25.00)	24.3611
2020's	1 (2.78)	2.80

Authors	Studies
Cavalli, A	1
Bolognesi, ML	1
Minarini, A	1
Rosini, M	1
Tumiatti, V	1
Recanatini, M	1
Melchiorre, C	1
Rascol, O	4
Cochen de Cock, V	1
Pavy-Le Traon, A	1
Foubert-Samier, A	1
Thalamas, C	1
Sommet, A	1
Rousseau, V	1
Perez-Lloret, S	1
Fabbri, M	1
Azulay, JP	1
Corvol, JC	1
Couratier, P	1
Damier, P	1
Defebvre, L	1
Durif, F	1
Geny, C	1
Houeto, JL	1
Remy, P	1
Tranchant, C	1
Verin, M	1
Tison, F	1
Meissner, WG	1
Kim, KI	1
Chung, YC	1
Jin, BK	1
Kostić, V	1
Dzoljić, E	1
Todorović, Z	1
Mijajlović, M	1
Svetel, M	1
Stefanova, E	1
Dragasević, N	1
Petrović, I	1
Milosević, M	1
Kovacević, I	2
Miljković, B	2
Pokrajac, M	2
Prostran, M	1
Sharifi, H	1
Nayebi, AM	1
Farajnia, S	1
Haddadi, R	1
Berghauzen-Maciejewska, K	1
Kuter, K	1
Kolasiewicz, W	1
Głowacka, U	1
Dziubina, A	1
Ossowska, K	1
Wardas, J	1
Podurgiel, SJ	1
Milligan, MN	1
Yohn, SE	1
Purcell, LJ	1
Contreras-Mora, HM	1
Correa, M	1
Salamone, JD	1
Demchuk, ND	1
Shutov, AA	1
McMillan, PJ	1
White, SS	1
Franklin, A	1
Greenup, JL	1
Leverenz, JB	1
Raskind, MA	1
Szot, P	1
Zhang, F	1
Zhou, H	1
Wilson, BC	1
Shi, JS	1
Hong, JS	1
Gao, HM	1
Kohl, Z	1
Winner, B	1
Ubhi, K	1
Rockenstein, E	1
Mante, M	1
Münch, M	1
Barlow, C	1
Carter, T	1
Masliah, E	1
Winkler, J	1
Inden, M	1
Abe, M	1
Minamino, H	1
Takata, K	1
Yoshimoto, K	1
Tooyama, I	1
Kitamura, Y	1
Montastruc, JL	4
Schmitt, L	1
Bagheri, H	1
Fregni, F	4
Santos, CM	2
Myczkowski, ML	1
Rigolino, R	1
Gallucci-Neto, J	1
Barbosa, ER	3
Valente, KD	2
Pascual-Leone, A	3
Marcolin, MA	3
Djordjevic, S	1
Vuksanovic, J	1
Boggio, PS	2
Bermpohl, F	2
Mansur, CG	1
Rosa, M	1
Rumi, DO	1
Odebrecht Rosa, M	1
Rigonatti, SP	2
Araujo Silva, MT	1
Lee, KH	1
Blaha, CD	1
Harris, BT	1
Cooper, S	1
Hitti, FL	1
Leiter, JC	1
Roberts, DW	1
Kim, U	1
Ono, CR	1
Buchpiguel, C	1
Cardoso, EF	1
Martins Maia, F	1
Luis Myczkowski, M	1
Coracini, K	1
Lopes Vieira, A	1
Melo, LM	1
Sato, JR	1
Antonio Marcolin, M	1
Cruz, AC	1
Reis Barbosa, E	1
Amaro, E	1
Preskorn, SH	2
Garcia-Monco, JC	1
Padierna, A	1
Gomez Beldarrain, M	1
Fabre, N	1
Blin, O	2
Senard, JM	3
Rascol, A	2
Huszonek, JJ	1
Waters, CH	1
Chamontin, B	1
Tran, MA	2
Llau, ME	1
Toyama, SC	1
Iacono, RP	1
Lauterbach, EC	1
Hesselink, JM	1
Pelat, M	1
Verwaerde, P	1
Brefel-Courbon, C	1
Shad, MU	1
Marsh, C	1
Yamato, H	1
Kannari, K	1
Shen, H	1
Suda, T	1
Matsunaga, M	1
Bilbao Garay, J	1
Mesa Plaza, N	1
Castilla Castellano, V	1
Dhimes Tejada, P	1
Jermain, DM	1
Hughes, PL	1
Follender, AB	1
Caley, CF	1
Friedman, JH	1
Jansen, EN	1
Kölling, P	1
Suchowersky, O	1
deVries, J	1

Trial	Enrollment	Study Type	Start Date	Status
A Pilot Study of Repetitive Transcranial Magnetic Stimulation for Improvement of Depression in Amyotrophic Lateral Sclerosis[NCT03892863]	0 participants (Actual)	Interventional	2019-11-15	Withdrawn (stopped due to Participants were not able to stay for two weeks near our center.)
Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial[NCT01080794]	61 participants (Actual)	Interventional	2010-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

To establish the safety and tolerability of rTMS in Parkinson's Disease. (NCT01080794)
Timeframe: Baseline through Month 6

Apathy Evaluation Scale (AES)

Intervention	incidents of an adverse event (Number)
Double rTMS	18
M1 Active rTMS + DLPFC Sham rTMS	14
DLPFC Active rTMS + M1 Sham rTMS	1
Double Sham rTMS	1

To evaluate apathy in Parkinson's Disease. The AES mean scores were reported for each group at each time point. The AES Score Range is 0-42, where higher the score indicates greater severity of the apathy symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Beck Depression Inventory (BDI-II)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	18.7	18.1	19.0	19.3	15.8
Double rTMS	15.6	16.2	17	16.9	17.8
Double Sham rTMS	16.3	15.5	15.0	16.1	16.2
M1 Active rTMS + DLPFC Sham rTMS	15.9	16.9	14.6	15.1	12.4

To assess mood symptoms in Parkinson's Disease. The BDI-II mean scores were reported for each group at each time point. The BDI-II Score Range is 0 - 63, where higher the score indicates greater severity of the mood symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Clinical Anxiety Scale (CAS)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	21.7	18.2	20.2	19.0	15.7
Double rTMS	23.2	20.7	16.4	17.9	20.1
Double Sham rTMS	18.8	13.7	13.1	14.7	16.8
M1 Active rTMS + DLPFC Sham rTMS	18.5	16.5	16.7	19.1	16.3

To evaluate anxiety in Parkinson's Disease. The CAS mean scores were reported for each group at each time point. The CAS Score Range is 0 - 100, where higher the score indicates greater severity of the anxiety symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Global Impression Scales

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	33.4	27.6	30.8	31.4	24.8
Double rTMS	36.3	34.2	31.7	33.1	33.4
Double Sham rTMS	37.5	32.4	28.2	28.5	35.0
M1 Active rTMS + DLPFC Sham rTMS	34.3	31.0	30.8	27.3	28.1

To assess symptom severity and treatment response in Parkinson's Disease. The CGI mean scores were reported for each group at each time point. The CGI Score Range is 1 - 8, where higher the score indicates greater severity of illness or worsening of illness. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Hamilton Depression Scale (HAM-D)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment): Severity	Week 1 Post Treatment: Severity	Week 1 Post Treatment: Improvement	Month 1 Post Treatment: Severity	Month 1 Post Treatment: Improvement	Month 3 Post Treatment: Severity	Month 3 Post Treatment: Improvement	Month 6 Post Treatment: Severity	Month 6 Post Treatment: Improvement
DLPFC Active rTMS + M1 Sham rTMS	4.3	4.7	3.5	4.4	3.7	4.4	3.6	4.3	3.7
Double rTMS	4.9	4.8	3.6	4.4	3.5	4.6	3.7	4.2	3.5
Double Sham rTMS	3.6	3.9	3.0	4.1	3.5	4.4	3.6	4.6	3.4
M1 Active rTMS + DLPFC Sham rTMS	4.7	4.9	3.5	4.8	3.8	3.8	3.4	5.0	4.2

"To evaluate the depressive mood symptoms in PD.~The HAM-D mean scores were reported for each group at each time point. The HAM-D Score Range is 0 - 56, where higher the score indicates greater severity of depressive mood symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Montreal Cognitive Assessment (MoCA)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post-Treatment	Month 1 Post-Treatment	Month 3 Post-Treatment	Month 6 Post-Treatment
DLPFC Active rTMS + M1 Sham rTMS	13.8	9.4	12.4	10.4	10.4
Double rTMS	15.2	11.3	10.6	10.7	10.4
Double Sham rTMS	14.1	9.3	8.0	11.1	10.4
M1 Active rTMS + DLPFC Sham rTMS	16.7	11.2	10.1	10.1	8.6

To screen and follow cognitive function in Parkinson's Disease. The MoCA mean scores were reported for each group at each time point. The MoCA Score Range is 0 - 30, where 26-30 indicates normal cognition. (NCT01080794)
Timeframe: pre-treatment; 0,1,3, and 6 months post-treatment

Motor Subscale of the Unified Parkinson's Disease Rating Scale (UPDRS Part III)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	27.3	26.3	26.8	26.7	26.6
Double rTMS	28.2	26.8	28.8	26.5	28.0
Double Sham rTMS	26.2	27.8	28.7	24.9	28.0
M1 Active rTMS + DLPFC Sham rTMS	26.6	27.1	27.2	25.3	27.9

"To evaluate the motor symptoms in Parkinson's Disease.~The UPDRS-III mean scores were reported for each group at each time point. The UPDRS-III Score Range is 0 - 56, where higher the score indicates greater severity of the motor symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Parkinson's Disease Questionnaire 39 (PDQ-39)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post-Treatment	Month 1 Post-Treatment	Month 3 Post-Treatment	Month 6 Post-Treatment
DLPFC Active rTMS + M1 Sham rTMS	32.8	30.3	29.3	31.5	28.8
Double rTMS	32.3	31.2	30.1	29.6	30.5
Double Sham rTMS	28.9	28.2	28.6	28.6	29.0
M1 Active rTMS + DLPFC Sham rTMS	33.1	27.4	28.1	33.2	30.6

To assess the quality of life (QOL) in Parkinson's Disease. The PDQ-39 mean scores were reported for each group at each time point. The PDQ-39 Score Range is 0 - 156, where higher the score indicates greater impact on quality of life. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Unified Parkinson's Disease Rating Scale (UPDRS) Parts I, II, and IV

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	51.9	46.8	49.4	49.4	49
Double rTMS	57.6	51.2	49.9	51.7	50.5
Double Sham rTMS	55.5	43.1	40.9	43.1	47.5
M1 Active rTMS + DLPFC Sham rTMS	61.5	60.7	56.8	53.1	48.3

"To assess apathy, cognition, depression, activities of daily living (ADL), quality of life (QOL), and motor symptoms in Parkinson's Disease.~The UPDRS I, II, IV total mean scores were reported for each group at each time point. The UPDRS I, II, IV scores were added together for each patient, with a total score range of 0 - 91, where higher the score indicates greater severity of the symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Article	Year
Multi-target-directed ligands to combat neurodegenerative diseases. Journal of medicinal chemistry, 2008, Feb-14, Volume: 51, Issue:3 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium	2008
[Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine]. Revue neurologique, 2003, Volume: 159, Issue:4 Topics: Antidepressive Agents; Antiparkinson Agents; Bromocriptine; Citalopram; Depressive Disorder; Dopamin	2003
[Serotonin syndrome: report of a fatal case and review of the literature]. Revista clinica espanola, 2002, Volume: 202, Issue:4 Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism	2002

Article	Year
Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:7 Topics: Double-Blind Method; Fluoxetine; Humans; Multiple System Atrophy; Parkinson Disease; Quality of Life	2021
Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. Vojnosanitetski pregled, 2012, Volume: 69, Issue:12 Topics: Activities of Daily Living; Affect; Antidepressive Agents, Second-Generation; Dementia; Depression;	2012
[Correction of motor and affective symptoms of parkinsonism by selective serotonine reuptake inhibition antidepressant]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008, Volume: 108, Issue:9 Topics: Adult; Aged; Female; Fluoxetine; Humans; Male; Middle Aged; Mood Disorders; Parkinson Disease; Psych	2008
Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:8 Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Electric	2004
Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:8 Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Electric	2004
Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:8 Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Electric	2004
Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:8 Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Electric	2004
Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:9 Topics: Aged; Antiparkinson Agents; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Fe	2005
Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. Neurology, 2006, Jun-13, Volume: 66, Issue:11 Topics: Aged; Antidepressive Agents; Brain; Cerebrovascular Circulation; Combined Modality Therapy; Depressi	2006
rTMS treatment for depression in Parkinson's disease increases BOLD responses in the left prefrontal cortex. The international journal of neuropsychopharmacology, 2008, Volume: 11, Issue:2 Topics: Affect; Aged; Antidepressive Agents, Second-Generation; Brain Mapping; Combined Modality Therapy; De	2008
Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:3 Topics: Aged; Drug Therapy, Combination; Female; Fluoxetine; Humans; Levodopa; Male; Neurologic Examination;	1995
Fluoxetine and selegiline--lack of significant interaction. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1994, Volume: 21, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Depressive Disorder; Drug Interactions; Female; Fluoxetine; Humans;	1994
Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study. Fundamental & clinical pharmacology, 1998, Volume: 12, Issue:4 Topics: Aged; Aged, 80 and over; Animals; Blood Pressure; Denervation; Disease Models, Animal; Dogs; Female;	1998

Article	Year
Norfluoxetine Prevents Degeneration of Dopamine Neurons by Inhibiting Microglia-Derived Oxidative Stress in an MPTP Mouse Model of Parkinson's Disease. Mediators of inflammation, 2018, Volume: 2018 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons;	2018
Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats. Drug research, 2015, Volume: 65, Issue:8 Topics: Animals; Buspirone; Cerebrospinal Fluid; Fluoxetine; Interleukin-1beta; Interleukin-6; Male; Oxidopa	2015
Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease. Behavioural brain research, 2014, Sep-01, Volume: 271 Topics: Animals; Antidepressive Agents; Benzothiazoles; Depression; Disease Models, Animal; Dopamine Agonist	2014
Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015, Volume: 40, Issue:9 Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Rela	2015
Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain research, 2011, Feb-10, Volume: 1373 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Binding Sites; Cell Count; Dopamine beta-Hydroxylase; Fe	2011
Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism & related disorders, 2012, Volume: 18 Suppl 1 Topics: Animals; Cells, Cultured; Female; Fluoxetine; Microglia; Neurons; Neuroprotective Agents; Neurotoxic	2012
Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. The European journal of neuroscience, 2012, Volume: 35, Issue:1 Topics: Adult; alpha-Synuclein; Animals; Brain-Derived Neurotrophic Factor; Cell Proliferation; Disease Mode	2012
Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model. Journal of pharmacological sciences, 2012, Volume: 119, Issue:1 Topics: Animals; Behavior, Animal; Corpus Striatum; Dopaminergic Neurons; Fluoxetine; Histones; Levodopa; Ma	2012
Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study. Farmaco (Societa chimica italiana : 1989), 2005, Volume: 60, Issue:4 Topics: Adult; Aged; Chromatography, Liquid; Clinical Trials as Topic; Female; Fluoxetine; Humans; Male; Mas	2005
Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease. The European journal of neuroscience, 2006, Volume: 23, Issue:4 Topics: Action Potentials; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal;	2006
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic. Journal of psychiatric practice, 2008, Volume: 14, Issue:1 Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin;	2008
Selegiline, fluoxetine, and depression in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:3 Topics: Aged; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Ther	1995
Anticholinergic effects in a depressed parkinsonian patient. Journal of geriatric psychiatry and neurology, 1995, Volume: 8, Issue:2 Topics: Aged; Benztropine; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, C	1995
Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. Lancet (London, England), 1993, Feb-27, Volume: 341, Issue:8844 Topics: Adrenal Gland Neoplasms; Adult; Catecholamines; Diagnosis, Differential; Drug Interactions; Female;	1993
Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? The Annals of pharmacotherapy, 1994, Volume: 28, Issue:3 Topics: 1-Naphthylamine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Parkinson Disease	1994
Dopaminergic hallucinosis with fluoxetine in Parkinson's disease. The American journal of psychiatry, 1993, Volume: 150, Issue:11 Topics: Aged; Bromocriptine; Carbidopa; Fluoxetine; Hallucinations; Humans; Levodopa; Male; Parkinson Diseas	1993
Serotonin and Parkinson's disease. The American journal of psychiatry, 1993, Volume: 150, Issue:5 Topics: Basal Ganglia Diseases; Depressive Disorder; Dopamine; Drug Therapy, Combination; Fluoxetine; Humans	1993
The economic consequences of a drug-drug interaction. Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:1 Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Halo	2001
Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport, 2001, May-08, Volume: 12, Issue:6 Topics: Adrenergic Agents; Animals; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Extr	2001
Potential fluoxetine-selegiline interaction. The Annals of pharmacotherapy, 1992, Volume: 26, Issue:10 Topics: Aged; Ataxia; Depression; Drug Interactions; Female; Fluoxetine; Humans; Parkinson Disease; Selegili	1992
Does fluoxetine exacerbate Parkinson's disease? The Journal of clinical psychiatry, 1992, Volume: 53, Issue:8 Topics: Acute Disease; Adult; Aged; Ambulatory Care; Depressive Disorder; Female; Fluoxetine; Humans; Male;	1992
[Parkinsonism following addition of fluoxetine to treatment with neuroleptics or carbamazepine]. Nederlands tijdschrift voor geneeskunde, 1992, Apr-11, Volume: 136, Issue:15 Topics: Depression; Female; Fluoxetine; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease,	1992
Possible interactions between deprenyl and prozac. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1990, Volume: 17, Issue:3 Topics: Drug Interactions; Female; Fluoxetine; Humans; Middle Aged; Parkinson Disease; Selegiline	1990

fluoxetine and Idiopathic Parkinson Disease